Lynn Murray
Director de Operaciones en Clairvoyant Therapeutics, Inc. .
Perfil
Lynn Murray currently works as a Clinical Operations Manager at Clairvoyant Therapeutics, Inc.
Cargos activos de Lynn Murray
Empresas | Cargo | Inicio |
---|---|---|
Clairvoyant Therapeutics, Inc.
Clairvoyant Therapeutics, Inc. BiotechnologyHealth Technology Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022. | Director de Operaciones | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Clairvoyant Therapeutics, Inc.
Clairvoyant Therapeutics, Inc. BiotechnologyHealth Technology Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022. | Health Technology |
- Bolsa de valores
- Insiders
- Lynn Murray